Go Pro
→ Why Did Trump's Sons Put Money Into THIS Drone Company? (From Tim Sykes) (Ad)tc pixel Free CNXU Stock Alerts

Conexeu Sciences (CNXU) Competitors

Conexeu Sciences logo
$4.40 -0.35 (-7.37%)
Closing price 04:00 PM Eastern
Extended Trading
$4.60 +0.20 (+4.55%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CNXU vs. KIDS, DCTH, BWAY, TCMD, and NPCE

Should you buy Conexeu Sciences stock or one of its competitors? Conexeu Sciences's main competitors and comparable companies include OrthoPediatrics (KIDS), Delcath Systems (DCTH), Brainsway (BWAY), Tactile Systems Technology (TCMD), and NeuroPace (NPCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Conexeu Sciences compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

OrthoPediatrics presently has a consensus price target of $26.44, suggesting a potential upside of 16.19%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 354.55%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than OrthoPediatrics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Conexeu Sciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -15.72%. OrthoPediatrics' return on equity of -8.10% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
OrthoPediatrics-15.72% -8.10% -5.54%
Conexeu Sciences N/A -200.20%-177.26%

Conexeu Sciences has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Conexeu Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$236.35M2.51-$39.65M-$1.68N/A
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A

In the previous week, OrthoPediatrics had 5 more articles in the media than Conexeu Sciences. MarketBeat recorded 6 mentions for OrthoPediatrics and 1 mentions for Conexeu Sciences. Conexeu Sciences' average media sentiment score of 0.97 beat OrthoPediatrics' score of 0.25 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OrthoPediatrics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

69.1% of OrthoPediatrics shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

OrthoPediatrics beats Conexeu Sciences on 8 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Delcath Systems has a net margin of 0.56% compared to Conexeu Sciences' net margin of 0.00%. Delcath Systems' return on equity of 0.46% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Delcath Systems0.56% 0.46% 0.42%
Conexeu Sciences N/A -200.20%-177.26%

Delcath Systems has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delcath Systems$85.23M6.68$2.70M$0.011,640.00
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A

In the previous week, Delcath Systems and Delcath Systems both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 0.97 beat Delcath Systems' score of 0.26 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Delcath Systems
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Delcath Systems presently has a consensus target price of $23.17, indicating a potential upside of 41.26%. Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 354.55%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Delcath Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Delcath Systems beats Conexeu Sciences on 12 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Brainsway currently has a consensus price target of $18.20, indicating a potential upside of 33.53%. Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 354.55%. Given Conexeu Sciences' higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainsway
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Brainsway has a net margin of 15.65% compared to Conexeu Sciences' net margin of 0.00%. Brainsway's return on equity of 12.74% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Brainsway15.65% 12.74% 8.17%
Conexeu Sciences N/A -200.20%-177.26%

In the previous week, Brainsway had 3 more articles in the media than Conexeu Sciences. MarketBeat recorded 4 mentions for Brainsway and 1 mentions for Conexeu Sciences. Conexeu Sciences' average media sentiment score of 0.97 beat Brainsway's score of 0.88 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Brainsway
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

30.1% of Brainsway shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Brainsway has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainsway$52.22M10.50$7.57M$0.4430.98
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A

Summary

Brainsway beats Conexeu Sciences on 12 of the 14 factors compared between the two stocks.

How does Conexeu Sciences compare to Tactile Systems Technology?

Conexeu Sciences (NASDAQ:CNXU) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

83.4% of Tactile Systems Technology shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Conexeu Sciences and Conexeu Sciences both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 0.97 beat Tactile Systems Technology's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tactile Systems Technology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Conexeu Sciences presently has a consensus target price of $20.00, suggesting a potential upside of 354.55%. Tactile Systems Technology has a consensus target price of $38.40, suggesting a potential upside of 69.20%. Given Conexeu Sciences' higher probable upside, equities research analysts plainly believe Conexeu Sciences is more favorable than Tactile Systems Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Tactile Systems Technology
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Tactile Systems Technology has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A
Tactile Systems Technology$329.52M1.56$19.09M$1.0821.01

Tactile Systems Technology has a net margin of 7.10% compared to Conexeu Sciences' net margin of 0.00%. Tactile Systems Technology's return on equity of 11.49% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A -200.20% -177.26%
Tactile Systems Technology 7.10%11.49%9.17%

Summary

Tactile Systems Technology beats Conexeu Sciences on 11 of the 13 factors compared between the two stocks.

How does Conexeu Sciences compare to NeuroPace?

Conexeu Sciences (NASDAQ:CNXU) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Conexeu Sciences has a net margin of 0.00% compared to NeuroPace's net margin of -19.34%. NeuroPace's return on equity of -105.64% beat Conexeu Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A -200.20% -177.26%
NeuroPace -19.34%-105.64%-16.51%

Conexeu Sciences currently has a consensus price target of $20.00, suggesting a potential upside of 354.55%. NeuroPace has a consensus price target of $19.33, suggesting a potential upside of 31.43%. Given Conexeu Sciences' higher possible upside, research analysts clearly believe Conexeu Sciences is more favorable than NeuroPace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
NeuroPace
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, NeuroPace had 2 more articles in the media than Conexeu Sciences. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Conexeu Sciences. Conexeu Sciences' average media sentiment score of 0.97 beat NeuroPace's score of 0.47 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroPace
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.8% of NeuroPace shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Conexeu Sciences has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Conexeu Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A
NeuroPace$99.99M5.05-$21.47M-$0.57N/A

Summary

NeuroPace beats Conexeu Sciences on 9 of the 15 factors compared between the two stocks.

Get Conexeu Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNXU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNXU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNXU vs. The Competition

Export
MetricConexeu SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$133.98M$5.55B$7.27B$13.28B
Dividend YieldN/A1.80%2.53%12.80%
P/E Ratio-11.0025.61275.1425.86
Price / SalesN/A72.21683.78116.28
Price / CashN/A33.1128.0434.72
Price / BookN/A5.9810.736.45
Net Income-$3.92M$152.13M$3.49B$360.08M
7 Day Performance-1.12%1.97%2.37%2.35%
1 Month Performance-50.51%-2.82%-1.73%-2.48%
1 Year PerformanceN/A7.53%17.91%6.42%

Conexeu Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNXU
Conexeu Sciences
2.6572 of 5 stars		$4.40
-7.4%		$20.00
+354.5%		N/A$133.98MN/AN/A4
KIDS
OrthoPediatrics
3.775 of 5 stars		$21.82
+0.2%		$26.44
+21.2%		+16.5%$568.67M$236.35MN/A602
DCTH
Delcath Systems
2.8499 of 5 stars		$16.11
-0.9%		$23.17
+43.8%		+39.6%$563.85M$85.23M1,612.61156
BWAY
Brainsway
4.657 of 5 stars		$13.61
+0.6%		$18.20
+33.7%		+75.4%$544.01M$52.22M30.93129
TCMD
Tactile Systems Technology
3.3654 of 5 stars		$22.20
-1.6%		$38.40
+73.0%		+62.5%$511.04M$329.52M20.561,086

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CNXU) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners
A councilman backed AI — then 13 bullets hit his front door
Thirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...
Stansberry Research | Sponsoredtc pixel
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
CFA: Decentralized AI is the Next Wave
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
Why Did Trump's Sons Put Money Into THIS Drone Company?
Eric Trump and Donald Trump Jr. are reportedly backing an American drone manufacturer competing for a share of...
Tim Sykes | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Iran War WARNING: Something Just Changed
A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...
Banyan Hill Publishing | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel